HomeThorne Healthtech Extends Collaboration With Astrazeneca to Advance Drug Discovery

Thorne Healthtech Extends Collaboration With Astrazeneca to Advance Drug Discovery

Thorne HealthTech, Inc., a leader in developing innovative solutions for a personalized approach to health and wellness, announced Aug. 4th a two-year extension of the collaboration with AstraZeneca, a leading biopharmaceuticals company. 

A History of Collaborations and Buy-Offs

This is not the first time Thorne engages into collaborations or buys other companies to improve its products or advance research. 

In December of 2021,Thorne HealthTech’s health intelligence unit, Onegevity, entered into a collaboration with Legacy Community Health Services, Inc., the largest Federally Qualified Health Center in Texas, and its advisor and venture studio Design Run Group.

Combining a proprietary, multi-omic platform with AI to provide actionable insights to customers with enhanced information and effective products to improve their health, Onegevity  – Thorne HealthTech’s AI and health intelligence engine – was going to provide software to power multi-faceted assessments – from 3D body shape measurements, cognition testing, strength and balance and more – within the Senior Care Clinic, as well as data analysis and insight generation using its AI and machine learning algorithms. 

This year, March 3rd, Thorne HealthTech announced it has acquired Nutrativa LLC, an innovative company leveraging two-dimensional (“2D”) high-speed printing technology. The aim of this endeavor is for Thorne HealthTech to launch a dissolvable supplement disc product line, beginning with a children’s multi-vitamin supplement disc that will provide a high-quality and fuss-free solution for healthy growth and development for children ages four to 12. The quick-dissolving, portable, and versatile multi-vitamin disc combines the highest quality forms of vitamins, minerals, and other nutrients, and is free of sugar, gluten, dairy, soy, fillers, and gelatin. This innovative disc technology also provides a more absorbable form of delivery.

In May, Thorne relaunched its Gut Health Test with the inclusion of its patent-pending Microbiome Wipe, a first-to-market approach to microbiome testing. Thorne’s Microbiome Wipe revolutionizes the user experience of microbiome testing by eliminating inconvenient stool sampling that often leads users to either postpone the test or not take it at all.

This one-of-a-kind innovation, which is now included in Thorne’s Gut Health Test kit beginning today, makes stool sample collection convenient and simple, improving the user experience while providing the user with cutting-edge analyses and personalized results with increased efficacy.

Thorne’s Disease Discovery Platform Will Be Incorporated Into AZ

Now, the extended collaboration with AZ will see the internalization of Thorne’s disease discovery platform into AZ for further evaluation and to gain insight into additional uses for AZ molecules.

Thorne’s cloud-based AI disease discovery system integrates biology and chemistry evidence to create compound innovations for new product development in both nutrition and pharmaceutical fields. The system, which leverages a proprietary multi-omic platform and Thorne’s AI models, has been validated by multiple external clinical research in peer-reviewed publications. 

“Our collaboration with AstraZeneca brings together traditional biology with innovative AI-driven technologies, representing the future of drug discovery,” said Chairman and CEO of Thorne HealthTech, Paul Jacobson. “Together, we will have an improved understanding of the underlying disease mechanisms to further identify novel and biologically plausible drug targets which we know are incredibly complex.”

“Embedding cutting-edge data science and AI within our research and development strategies is helping transform our ability to uncover novel drivers of disease,” said Senior Vice President, Discovery Sciences, AstraZeneca, Mike Snowden. “This data-driven approach to drug discovery has the potential to expand our knowledge of disease biology and allow us to bring life-saving medicines to patients faster than ever before.”

About Thorne HealthTech

Thorne HealthTech is a leader in developing innovative solutions for delivering personalized approaches to health and wellness. As a science-driven wellness company that empowers individuals with the support, education, and solutions they need to achieve healthy aging – living healthier longer – Thorne utilizes testing and data to create improved product efficacy and to deliver personalized solutions to consumers, health professionals, and corporations. Predicated on the power of the individual, Thorne leverages artificial intelligence models to provide insights and personalized data, products, and services that help individuals take a proactive and actionable approach to improve and maintain their health over a lifetime. Thorne is the only supplement manufacturer that collaborates with Mayo Clinic on health and wellness research and content, and is trusted by more than four million customers, 45,000+ health-care professionals, thousands of professional athletes, and more than 100 professional sports teams and U.S. National Teams. 

About AstraZeneca

AstraZeneca is a global, science-led, patient-focused pharmaceutical, which tirelessly seeks to realize the potential of what science can do.

They are focused on creating genuinely innovative medicines and improving access to them. In this way, they deliver the greatest benefit to patients, healthcare systems and societies globally.

AZ have three priorities designed to deliver our growth through innovation strategy. 

  • Accelerating the next wave of new molecular entities, building their capabilities in immunology and rare diseases, pursuing new scientific modalities and driving R&D productivity. 
  • Meeting their growth and profitability goals through successful innovation and commercial excellence, as well as completing the Alexion acquisition. 
  • Contributing to the enterprise and to society, with a focus on inclusion and diversity, lifelong learning, improving access to healthcare, environmental protection, and ethics and transparency, as well as delivering their Ambition Zero Carbon programme
Astellas Partners With Kelonia to Develop New Immuno-Oncology Therapies